GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available drugs that hit two targets, but other big pharma companies are also developing trispecific antibodies.

The post GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma appeared first on MedCity News.